Manufacturing sterile injectables today is more complex than ever. Navigating stringent aseptic requirements, evolving regulatory expectations and the need for significant specialized investment has made the path to market increasingly challenging.
A fragmented approach across development, drug substance manufacturing and fill finish remains a common industry practice that can introduce critical vulnerabilities. With every handoff, the risks multiply: the potential for contamination increases, tech transfer misalignments can cause delays, regulatory compliance becomes more complicated and supply chains grow more difficult to manage. As these issues compound, they create delays that slow timelines and impact patients’ access to potentially critical therapies.
Kindeva’s Bridgeton facility is purpose-built to change that. Bringing together advanced isolator technology, flexible filling formats, real-time automation and integrated services under one roof, Bridgeton offers a streamlined, scalable and Annex 1-compliant solution to bring complex injectable products to market more efficiently.
In this eBook, you will discover how Bridgeton was purpose-built for progress with:
- Isolator technology and automated filling lines
- Integrated fill finish, device manufacturing and final packaging in one facility
- Scalability from clinical trial batches to full-scale commercial supply
- Annex 1-compliant infrastructure
With over 155,000 square feet of cGMP aseptic operations space, 150 million unit annual capacity and world-class sterile manufacturing technology, Bridgeton is designed to deliver excellence throughout your injectable project.
Download the Bridgeton eBook to explore how we can transform tomorrow together at our world-class sterile fill finish facility today!
Ready to find out what a true CDMO partnership feels like? Let us show you how our world-class facilities, technologies and analytical capabilities can provide your project with strategic value that bridges beyond manufacturing.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Turning media fill data into stronger aseptic control in an Annex 1 era
Media fills provide an important demonstration of aseptic process performance, as the information gathered during a simulation gives manufacturers a stronger understanding of how the process behaves over time. As companies must now translate their media fill processes to meet Annex 1 expectations, the way this information is reviewed can provide valuable insight into aseptic […]
Learn More
Rethinking media fill strategy in the Annex 1 era
Media fills play a central role in aseptic process validation, providing a practical demonstration that a manufacturing process can be carried out without introducing microbial contamination. However, under the revised EU GMP Annex 1 guidance, the focus has shifted, and an acceptable final incubation result is no longer sufficient on its own. Now, media fills […]
Learn More
What’s behind the decisions shaping successful fill finish programs?
Advanced equipment and available cleanroom capacity are important considerations when choosing a sterile fill finish CDMO partner, but they only form part of the decision. As a drug program nears cGMP manufacturing, careful consideration of technical, quality, and operational readiness is essential, as it shapes how confidently a program can progress. These considerations take place […]
Learn More
Building sterile injectable manufacturing capacity for growing GLP-1 demand
Glucagon-like peptide-1 (GLP-1) receptor agonists are being prescribed more frequently, increasing pressure on sterile injectable manufacturing networks. To effectively serve expanding patient populations, developers must increase output while maintaining product quality and regulatory compliance without disrupting the supply of other therapies. Meeting the growing GLP-1 demand requires manufacturing models that can manage high-volume programs alongside […]
Learn More
Meeting the challenges of fill finish manufacturing
How flexible infrastructure and early manufacturing expertise can help drug developers respond to changing demand With rising demand for glucagon-like peptide-1 (GLP-1) medicines, continued progress in biologics and the expansion of self-administered treatments, new expectations are being placed on sterile fill finish operations. Manufacturers must accommodate different container formats and production volumes while maintaining consistent […]
Learn More
Parenteral precision: Upstream formulation handling before sterile fill finish
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. In our first blog, we explored how sterile fill finish operations are designed around […]
Learn More
Delivering tomorrow’s injectables, today
Injectable therapies are entering a new phase of complexity. Biologics, personalized medicines and combination products are increasing demand for delivery systems that must adapt to more diverse formats and patient needs. Expectations around speed and compliance also continue to rise across the development lifecycle, placing greater pressure on how these systems are designed and scaled. […]
Learn More
Q&A: Navigating tech transfer and production pitfalls
Successful tech transfer alignment requires robust risk management and precise operational planning. When communication gaps or unforeseen supply chain hurdles emerge, project timelines and product quality are often the first to be affected. In this Q&A, we explore the common pitfalls of pharmaceutical tech transfers, including how to protect critical milestones without compromising safety and […]
Learn More
Webinar | Beyond the filling suite: How modular facility design supports sterile manufacturing success
Sterile manufacturing requirements are fast evolving, which means that many organizations are reassessing whether their legacy facilities can support future operational and regulatory demands. In this webinar, John Wichelt, Vice President and General Manager at Kindeva’s Bridgeton site, explores what a modern sterile fill finish facility needs to look like in this new era. Drawing […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.